

PLOS Neglected Tropical Diseases

Single-cell RNA sequencing of Plasmodium vivax sporozoites reveals stage- and species-specific transcriptomic signatures

--Manuscript Draft--

Manuscript Number:	PNTD-D-21-01772
Full Title:	Single-cell RNA sequencing of Plasmodium vivax sporozoites reveals stage- and species-specific transcriptomic signatures
Short Title:	Single-cell RNA sequencing of Plasmodium vivax sporozoites
Article Type:	Research Article
Keywords:	Plasmodium vivax; single-cell RNA sequencing; sporozoite; malaria; systems biology
Abstract:	<p>Background Plasmodium vivax sporozoites reside in the salivary glands of a mosquito before infecting a human host. Previous transcriptome-wide studies in populations of these forms were limited in their ability to elucidate cell-to-cell variation, thereby masking cellular states potentially important in understanding transmission outcomes.</p> <p>Methodology/Principal findings In this study, we performed transcription profiling on 9,947 P. vivax sporozoites to assess the extent to which they differ at single-cell resolution. We show that sporozoites residing in the mosquito's salivary glands exist in distinct developmental states, as defined by their transcriptomic signatures. Additionally, relative to P. falciparum, P. vivax displays overlapping and unique gene usage patterns, highlighting conserved and species-specific gene programs. Notably, distinguishing P. vivax from P. falciparum were a subset of P. vivax sporozoites expressing genes associated with translational regulation and repression. Finally, our comparison of single-cell transcriptomic data from P. vivax sporozoite and erythrocytic forms reveals gene usage patterns unique to sporozoites.</p> <p>Conclusions/Significance In defining the transcriptomic signatures of individual P. vivax sporozoites, our work provides new insights into the factors driving their developmental trajectory and lays the groundwork for a more comprehensive P. vivax cell atlas.</p>
Additional Information:	
Question	Response
Financial Disclosure Enter a financial disclosure statement that describes the sources of funding for the work included in this submission. Review the submission guidelines for detailed requirements. View published research articles from PLOS NTDs for specific examples. This statement is required for submission and will appear in the published article if the submission is accepted. Please make sure it is accurate.	<p>This work was supported by the Agence Nationale de la Recherche (https://anr.fr, ANR-17-CE13-0025 to A.A.R., G.S., I.M.), the National Health and Medical Research Council of Australia (www.nhmrc.gov.au, NHMRC; 1092789 and 1134989 to I.M.), and a NHMRC Principal Research Fellowship (www.nhmrc.gov.au, 1155075 to I.M). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>

Unfunded studies

Enter: *The author(s) received no specific funding for this work.*

Funded studies

Enter a statement with the following details:

- Initials of the authors who received each award
- Grant numbers awarded to each author
- The full name of each funder
- URL of each funder website
- Did the sponsors or funders play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript?
- **NO** - Include this sentence at the end of your statement: *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*
- **YES** - Specify the role(s) played.

* typeset

Competing Interests

Use the instructions below to enter a competing interest statement for this submission. On behalf of all authors, disclose any [competing interests](#) that could be perceived to bias this work—acknowledging all financial support and any other relevant financial or non-financial competing interests.

This statement **will appear in the published article** if the submission is accepted. Please make sure it is accurate. View published research articles from [PLOS NTDs](#) for specific examples.

The authors have declared that no competing interests exist.

NO authors have competing interests

Enter: *The authors have declared that no competing interests exist.*

Authors with competing interests

Enter competing interest details beginning with this statement:

I have read the journal's policy and the authors of this manuscript have the following competing interests: [insert competing interests here]

* typeset

This statement is **required** for submission and **will appear in the published article** if the submission is accepted. Please make sure it is accurate and that any funding sources listed in your Funding Information later in the submission form are also declared in your Financial Disclosure statement.

Data Availability

Authors are required to make all data underlying the findings described fully available, without restriction, and from the time of publication. PLOS allows rare exceptions to address legal and ethical concerns. See the [PLOS Data Policy](#) and [FAQ](#) for detailed information.

Yes - all data are fully available without restriction

A Data Availability Statement describing where the data can be found is required at submission. Your answers to this question constitute the Data Availability Statement and **will be published in the article**, if accepted.

Important: Stating 'data available on request from the author' is not sufficient. If your data are only available upon request, select 'No' for the first question and explain your exceptional situation in the text box.

Do the authors confirm that all data underlying the findings described in their manuscript are fully available without restriction?

Describe where the data may be found in full sentences. If you are copying our sample text, replace any instances of XXX with the appropriate details.

- If the data are **held or will be held in a public repository**, include URLs, accession numbers or DOIs. If this information will only be available after acceptance, indicate this by ticking the box below. For example: *All XXX files are available from the XXX database (accession number(s) XXX, XXX).*
- If the data are all contained **within the manuscript and/or Supporting Information files**, enter the following: *All relevant data are within the manuscript and its Supporting Information files.*
- If neither of these applies but you are able to provide **details of access elsewhere**, with or without limitations, please do so. For example:

Data cannot be shared publicly because

All raw sequencing data generated from *P. vivax* sporozoites in this study will be deposited and accessible in the European Nucleotide Archive (www.ebi.ac.uk/ena/) upon acceptance of the manuscript.

of [XXX]. Data are available from the XXX Institutional Data Access / Ethics Committee (contact via XXX) for researchers who meet the criteria for access to confidential data.

The data underlying the results presented in the study are available from (include the name of the third party and contact information or URL).

- This text is appropriate if the data are owned by a third party and authors do not have permission to share the data.

* typeset

Additional data availability information:

Tick here if the URLs/accession numbers/DOIs will be available only after acceptance of the manuscript for publication so that we can ensure their inclusion before publication.



1 **Single-cell RNA sequencing of *Plasmodium vivax* sporozoites reveals** 2 **stage- and species-specific transcriptomic signatures**

3 **Short title:** Single-cell RNA sequencing of *Plasmodium vivax* sporozoites

4 Anthony A. Ruberto^{1,‡,ª}, Caitlin Bourke^{2,3,‡}, Amélie Vantoux⁴ Steven P. Maher⁵, Aaron Jex^{2,3},
5 Benoit Witkowski⁴, Georges Snounou⁶, Ivo Mueller^{1,2,3*}

6 ¹Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France

7 ²Division of Population Health and Immunity, Walter and Eliza Hall Institute of Medical
8 Research, Parkville, Victoria, Australia

9 ³Department of Medical Biology, The University of Melbourne, Parkville, Victoria Australia

10 ⁴ Malaria Molecular Epidemiology Unit, Institut Pasteur du Cambodge, Phnom Penh, Kingdom
11 of Cambodia

12 ⁵Center for Tropical and Emerging Global Diseases, University of Georgia, Athens 30602, USA

13 ⁶ Commissariat à l'Énergie Atomique et aux Énergies Alternatives-Université Paris Sud 11-
14 INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases (IMVA-HB),
15 Infectious Disease Models and Innovative Therapies (IDMIT) Department, Institut de Biologie
16 François Jacob (IBFJ), Direction de la Recherche Fondamentale (DRF), Fontenay-aux-Roses,
17 France

18

19 ‡ AAR and CB contributed equally to this work.

20 ª Current address: Center for Tropical and Emerging Global Diseases, University of Georgia,
21 Athens 30602, USA

22

23 * Corresponding author

24

25 E-mail: mueller@wehi.edu.au

26 **Abstract**

27 Background

28 *Plasmodium vivax* sporozoites reside in the salivary glands of a mosquito before infecting a
29 human **host**. Previous transcriptome-wide studies in populations of these **forms** were limited in
30 their ability to elucidate cell-to-cell variation, thereby masking cellular states potentially important
31 in understanding **transmission** outcomes.

32 Methodology/Principal findings

33 In this study, we performed transcription profiling on 9,947 *P. vivax* sporozoites to assess the
34 extent to which they differ at single-cell resolution. We show that sporozoites residing in the
35 mosquito's salivary glands exist in distinct developmental states, as defined by their
36 transcriptomic signatures. Additionally, relative to *P. falciparum*, *P. vivax* displays overlapping
37 and unique gene usage patterns, highlighting conserved and species-specific gene programs.
38 Notably, distinguishing *P. vivax* from *P. falciparum* were a subset of *P. vivax* sporozoites
39 expressing genes associated with translational regulation and repression. Finally, our
40 comparison of single-cell transcriptomic data from *P. vivax* sporozoite and erythrocytic forms
41 reveals gene usage patterns unique to sporozoites.

42 Conclusions/Significance

43 In defining the transcriptomic signatures of individual *P. vivax* sporozoites, our work provides
44 new insights into the factors driving their developmental trajectory and lays the groundwork for a
45 more comprehensive *P. vivax* cell atlas.

46 **Author summary**

47 *Plasmodium vivax* is the second most common cause of malaria worldwide. It is particularly
48 challenging for malaria elimination as it forms both active blood-stage infections, as well as
49 asymptomatic liver-stage infections that can persist for extended periods of time. The
50 reactivation of persister forms in the liver (hypnozoites) are responsible for relapsing infections
51 occurring weeks or months following primary infection via a mosquito bite. How *P. vivax* persists
52 in the liver remains a major gap in understanding of this organism. It has been hypothesized
53 that there is pre-programming of the infectious sporozoite while it is in the salivary-glands that
54 determines if the cell's fate once in the liver is to progress towards immediate liver stage
55 development or persist for long-periods as a hypnozoite. The aim of this study was to see if
56 such differences were distinguishable at the transcript level in salivary-gland sporozoites. While
57 we found significant variation amongst sporozoites, we did not find clear evidence that they are

58 clearly transcriptionally pre-programmed as has been suggested. Nevertheless, we highlight
59 several intriguing patterns that appear to be *P. vivax* specific relative to non-relapsing species
60 that cause malaria prompting further investigation.

61

62 Introduction

63 Malaria remains the most significant parasitic disease of humans globally, causing an
64 estimated 229 million infections and 409,000 deaths per year [1]. *Plasmodium* spp. are the
65 etiological agents of malaria, and at least five species are known to infect humans [1].
66 *Plasmodium falciparum* and *P. vivax* are the most prevalent, and both contribute significantly to
67 disease burden [2–4]. *Plasmodium* spp. infection in humans begins with the deposition of
68 sporozoites into the dermis when an infected *Anopheles* mosquito takes a blood meal [5]. While
69 sporozoites must undergo replication in the liver before mounting a blood-stage infection, *P.*
70 *vivax* sporozoites can develop into either a replicating or persisting (hypnozoite) form [6].
71 Hypnozoites can remain in the liver for weeks, months or years before reactivating to undergo
72 schizogony [7], leading to a relapsing blood-stage infection. Relapsing infections are estimated
73 to comprise up to 90% of *P. vivax* malaria cases in some regions [8–10]. Relapse-causing
74 hypnozoites, in addition to a high prevalence of sub-detectable and often asymptomatic blood-
75 stage infections, severely limit efforts to eradicate *P. vivax* malaria [3,11]. Recent modelling
76 suggests that eliminating *P. vivax* malaria is not possible without programs that specifically
77 target and cure hypnozoite infections [12].

78 The factors underlying the development of *P. vivax* sporozoites into replicating schizonts
79 or their persistence as hypnozoites and subsequent reactivation remain poorly defined. Key
80 questions regarding the regulation of hypnozoite biology have focused on how it differs
81 regionally, seasonally, and between strains. Relapse frequency varies by climate and
82 geographical region, with temperate strains exhibiting long periods of latency and tropical ones
83 relapsing at shorter intervals [13–15]. The observation that *P. vivax* may be able to regulate
84 hypnozoite formation in accordance with environmental conditions feeds into a hypothesis that
85 the developmental outcome within the liver may be pre-determined in the sporozoite [16,17]. In
86 addition, observations in humanised rodent livers have identified sympatric *P. vivax* strains with
87 stable differences in hypnozoite formation rates [18]. This points to genetic heterogeneity
88 among *P. vivax* sporozoites that may play a role in defining developmental fate, consistent with
89 the tachy- and bradysporozoites proposed by Lysenko et al. [16]. System-wide studies offer an
90 opportunity to find evidence for sporozoite pre-programming; however, previous analyses of *P.*
91 *vivax* sporozoites have been performed using bulk-sequencing approaches [19–21] which
92 obscure variation that might exist between individual parasites.

93 Single-cell RNA sequencing methods (scRNA-seq) constitute a recent advancement
94 applicable for assessing parasite-to-parasite differences. ScRNA-seq has differentiated multiple

95 transcriptomic states among individual *P. berghei* and *P. falciparum* sporozoites [22–25].
96 However, the extent to which *P. vivax* sporozoites vary at the single-cell level has not been
97 studied. Therefore, the application of scRNA-seq technology provides an opportunity to explore
98 heterogeneity amongst *P. vivax* sporozoites and examine the existence of distinct transcriptional
99 signatures that may help better understand the sporozoite's developmental fate.

100 In this study, we analyse the transcriptomes of 9,947 *P. vivax* sporozoites captured using
101 droplet-based scRNA-seq technology. We first cross-reference the data with sporozoite bulk
102 microarray and RNA-seq data to show consistent transcription of known genes upregulated in
103 sporozoites. Next, we represent the data in low dimensional space and identify sporozoites in
104 various transcriptomic states using both clustering and pseudotime trajectory methods. Finally,
105 we perform comparative analyses with publicly available *P. falciparum* sporozoite and *P. vivax*
106 blood-stage scRNA-seq data [23,26] and highlight both conserved and unique gene usage
107 patterns between sporozoites and erythrocytic forms. Overall, our work provides an important,
108 new resource for the malaria community by offering key insights into gene usage among *P.*
109 *vivax* sporozoites and the factors driving their developmental trajectory at a resolution
110 unattainable with bulk transcriptomics.

111 **Results**

112 **Processing, alignment, and pseudo-bulk assessment of *P. vivax* sporozoite scRNA-seq** 113 **data**

114 Given its high-throughput capability and prior use for sporozoites from murine-infecting
115 *Plasmodium* species [22,25], we used the 10X Genomics gene expression platform to profile
116 the transcriptomes of individual *P. vivax* sporozoites. We dissected and purified sporozoites
117 from the salivary glands of *An. dirus* mosquitoes in triplicate, with each replicate comprising
118 sporozoites derived from mosquitoes fed on a blood-meal from a different patient isolate.
119 Sporozoites dissected and released from mosquito salivary glands were kept in Hank's
120 Balanced Salt Solution at 4°C to minimise their activation. Sporozoites from each replicate were
121 infectious to primary human hepatocytes, as indicated by their ability to generate liver forms in a
122 384-well microtiter plate platform [27](Figs S1A-C). High-content analysis of liver-stage cultures
123 demonstrated that the sporozoites developed into hypnozoites and schizonts at a ratio of ~4:5
124 to ~6:4, depending on the case (Fig S1B). Between 5000-8000 sporozoites were loaded on a
125 10x Genomics' Chromium controller to partition the sporozoites, lyse, and uniquely-tag
126 transcripts. After tagging the transcripts, Illumina compatible short-read libraries were generated
127 and sequenced (Fig 1A and Fig S1D; S1 Table).

128 After aligning the sequencing data to the *P. vivax* P01 genome (Fig S2A), various
129 metrics confirmed that the libraries were of high quality (Fig S2B). An average of 48% of reads
130 across all replicates (638,820,734/1,340,791,021) mapped to the *P. vivax* P01 genome (Fig 1B),
131 with the remainder mapping to *An. dirus* (32%; 437,925,660/1,340,791,021) or not mapping at
132 all (20%; 264,044,627/1,340,791,021) (Figs S2C and S2D; S2 Table).

133 Until recently, the undefined nature of untranslated regions (UTRs) in the *P. vivax*
134 transcriptome was a gap in knowledge that restricted accurate quantification of transcription.
135 Given the 10x Genomics' scRNA-seq technology captures specifically the 3' end of transcripts
136 [28–30], RNA with long untranslated regions (UTRs) may be sequenced and mapped to the
137 genome but remain unquantified due to the incomplete annotation of these gene-flanking
138 regions. This is a documented challenge for 3' capture methods in *Plasmodium* and other non-
139 model organisms [22,25,31,32]. However, a more complete *P. vivax* transcriptome, including
140 UTRs, was recently reported [33] and was incorporated into our alignment pipeline (Fig S2A).
141 The inclusion of UTR coordinates resulted in a 1.3-fold increase of reads assigned to *P. vivax*
142 genes (Fig 1B; S3 Table). Compared to the alignment of reads using gene models lacking
143 UTRs, UTR inclusion resulted in the detection of an additional 417 genes and an increase in
144 counts for 1,182 genes (Fig S3A; S2 and S3 Tables). The largest increase was found for the
145 gene encoding gamete egress and sporozoite traversal protein (PVP01_125800) (Fig 1C; S3
146 Table). Other notable examples of genes with increased transcription included serine threonine
147 protein phosphatase 2B catalytic subunit A (PVP01_0117400), RNA-binding protein Musashi
148 (PVP01_0715100) and a conserved protein of unknown function (PVP01_1011800) (Fig 1C; S3
149 Table).

150 We next assessed the transcriptomes of 9,947 sporozoites obtained across all replicates
151 (Fig 1D). Of the 1,387 genes detected, 735 (53%) were detected in all three replicates (Fig 1E).
152 We observed high correlation in the transcription of genes detected in each replicate (mean
153 Pearson correlation coefficient, $R = 0.94$, $p < 0.05$; Fig S3B). Genes encoding for
154 circumsporozoite protein (PVP01_0835600), gamete egress and sporozoite traversal protein
155 (*gest*; PVP01_1258000), and sporozoite protein essential for cell traversal (*spect*;
156 PVP01_1212300) were among those with the highest transcription (S4 Table). Comparative
157 analyses of our data with bulk transcriptomic studies [19,20] revealed consistent detection of
158 various genes implicated in sporozoite biology (Fig 1F). These results paint a clearer picture of
159 gene usage in *P. vivax* sporozoites by incorporating each genes' UTRs and highlight the
160 capacity of scRNA-seq in assessing transcription in *P. vivax* sporozoites.

161 **Assessment of *P. vivax* sporozoites at single-cell resolution reveals transcriptomic**
162 **heterogeneity**

163 Our assessment of various per-cell metrics revealed differences in *P. vivax* sporozoites
164 at the transcript level, specifically in the distribution of unique molecular identifiers (UMIs); the
165 absolute number of transcripts [34], and genes detected in individual sporozoites across
166 replicates (Fig 2A). Using Uniform Manifold Approximation Projection (UMAP) of the data to
167 assess the transcriptomic differences visually, we found three distinct populations of sporozoites
168 (Fig 2B). Overlaying the UMI and genes detected data on the UMAP revealed sporozoites in
169 two main transcriptomic states: forms with higher gene usage (represented by the cells on the
170 left side of the UMAP) and forms with lower gene usage (on the right) (Fig 2C). We first
171 visualised transcription of well-described sporozoite membrane-associated and cell traversal
172 proteins (Fig 2D) [35–41]. Next, given that *P. vivax* parasites can form both replicating schizonts
173 and hypnozoites in the liver, we assessed the transcription profiles of genes implicated in
174 sporozoite developmental fating [19]. However, no clear pattern was observed, and sporozoites
175 in both populations transcribed genes encoding for membrane proteins, cell traversal and
176 initiation of invasion, and translational repression (Fig 2D).

177 To better understand the biological significance of these populations, we used an
178 unsupervised graph-based clustering algorithm [42] with a conservative grouping parameter (Fig
179 S4A) to systematically divide the sporozoites into three transcriptional clusters (Fig 3A),
180 consisting of 86 (cluster C1), 6,982 (cluster C2) and 2,879 (cluster C3) sporozoites,
181 respectively. The number of sporozoites in each cluster varied across replicates, indicating their
182 variability across different mosquito infections (Fig 3B). We next identified markers that define
183 the sporozoites in each cluster using the FindAllMarkers function in Seurat [43]. We defined a
184 marker as a gene detected in over 30% of cells in a given cluster and displaying significantly
185 greater transcription than the other clusters. In total, we found 159 markers (adjusted p-value <
186 0.05, S5 Table). Notably, sporozoite-specific protein, S10 (PVP01_0304200), was a marker for
187 sporozoites in C1 (Fig 3C; S5 Table), and has previously been shown to be highly transcribed in
188 midgut sporozoites [22,25]. C2 markers included circumsporozoite protein (PVP01_0835600);
189 early transcribed membrane protein (PVP01_0602100); TRAP-like protein (PVP01_1132600);
190 and sporozoite surface protein essential for liver stage development (PVP01_0938800) (Fig 3C;
191 S5 Table). Relative to C1 and C2, C3 had the fewest markers (20) (adjusted p-value < 0.05),
192 and of the markers identified, their changes in transcription were modest (average log₂- fold-
193 change range 0.28 – 0.84; Fig S4B). Markers in this cluster included genes involved in proton
194 transport (PVP01_0317600 and PVP01_1117400); redox response (PVP01_0835700 and

195 PVP01_1249700); and heat shock proteins (PVP01_1440500 and PVP01_1011500) (Fig 3C;
196 S5 Table).

197 **Trajectory-based pseudotime analysis reveals various transcription patterns in** 198 **sporozoites**

199 A caveat of using a cluster-based classification method is that cells are forced into
200 groups. In developing systems, such as sporozoites, cell transitions may be occurring more
201 continuously. The modest number of markers defining each cluster (S5 Table) suggested that a
202 continuum of transcriptional states may exist. We thus examined the transcriptional profiles of *P.*
203 *vivax* sporozoites in the context of pseudotime. We used Slingshot [44] to construct a trajectory
204 through the cells (Fig 4A). We observed differences in the distribution of sporozoites among
205 replicates over pseudotime. Sporozoites from replicate 1 were unimodal and primarily enriched
206 earlier in the trajectory, whereas sporozoites from replicates 2 and 3 were bimodal, with more
207 cells near the end of the trajectory (Fig 4B).

208 Next, to assess changes in transcription as cells progressed along the trajectory, we
209 modelled the transcription of each gene as a function of pseudotime [45]. We identified 1072
210 differentially transcribed genes (False discovery rate (FDR) < 0.01; S6 Table). Heatmap
211 visualisation of the data revealed three common patterns of how transcription changed over
212 pseudotime, including a gradual decrease, transient increase, and transient decrease (Fig 4C).
213 Our assessment of *P. vivax* sporozoites over pseudotime provides further insights into gene
214 usage, taking into account that cell transitions in these forms may occur more continuously.

215 ***P. vivax* sporozoites have distinct transcriptomic signatures relative to *P. falciparum*** 216 **sporozoites**

217 Whereas *P. vivax* sporozoites can form hypnozoites in hepatocytes, *P. falciparum*
218 sporozoites cannot. Therefore, we compared sporozoite transcriptomes from these two species
219 to assess the extent to which their gene expression profiles differ and search for signatures of
220 potential importance for hypnozoite formation. We first identified orthologous gene groupings to
221 allow for the cross-species comparison [46]. After subsampling the *P. vivax* data to balance the
222 proportions of *P. falciparum* [23] and *P. vivax* cells, we then combined the two species' datasets
223 to produce an integrated UMAP (Fig 5A top). The projection revealed that sporozoites in the *P.*
224 *vivax* and *P. falciparum* data mapped close together (Fig 5A top). The projection also revealed
225 distinct populations of *P. vivax* and *P. falciparum* cells, with the latter grouped by anatomical
226 location in the mosquito (Fig 5A bottom). The annotated *P. falciparum* data by mosquito location

227 and activation status allowed us to infer the transcriptomic status of *P. vivax* sporozoites. Using
228 these annotations as a guide, we grouped the sporozoites into four clusters (Fig 5B). Cluster 1
229 (ORTHO_C1) represented midgut/recently invaded sporozoites; cluster 2 (ORTHO_C2),
230 salivary gland sporozoites; and clusters 3 and 4 (ORTHO_3 and ORTHO_4), activating or
231 activated sporozoites. More than half of the *P. vivax* sporozoite data (63%, 949/1500) clustered
232 with the *P. falciparum* salivary gland sporozoites in ORTHO_C2 (Fig 5C and Fig S5A).
233 Interestingly, some *P. vivax* sporozoites were assigned to clusters ORTHO_C1, ORTHO_C3
234 and ORTHO_C4, shedding light on their intrinsic heterogeneity within the salivary glands of the
235 mosquito (Fig 5C and Fig S5A).

236 For each cluster, we identified genes that display greater transcription relative to the
237 other clusters and are conserved in both species, which we denote as conserved markers. In
238 total, we identified 12 conserved markers (adjusted p-value < 0.05; Fig S5C; S8 Table). Relative
239 to the other clusters, only sporozoites in the midgut/recently invaded and salivary gland clusters
240 (ORTHO_C1 and ORTHO_C2, respectively) had conserved gene signatures. We reasoned that
241 the disproportionate number of sporozoites for each species in ORTHO_C3 and ORTHO_C4
242 (Fig 5C and Fig S5A) contributed to the lack of conserved markers detected. Of the genes with
243 known function identified in ORTHO_C1, notable examples included sporozoite invasion-
244 associated protein 1 (PVP01_0307900 | PF3D7_0408600), important for sporozoite exit from
245 the mosquito midgut and colonization of the salivary gland [47] and sporozoite-specific protein
246 S10 (PVP01_0304200 | PF3D7_0404800), a marker implicated in salivary gland invasion
247 [22,25] (Fig S5C; S6 Table). In ORTHO_C2, genes linked to invasion (PVP01_1132600 |
248 PF3D7_0616500::TRAP-like protein) and liver stage development (PVP01_0938800 |
249 PF3D7_1137800::SPELD) were among the conserved markers identified (Fig S5C; S8 Table).

250 To elucidate species-specific transcription patterns within each cluster, we compared
251 transcript levels between species. Each cluster contained orthologues transcribed solely in *P.*
252 *vivax* or *P. falciparum* (Fig 5D left and Fig S5B; S9 Table). ORTHO_C4, which was composed
253 almost entirely of *P. vivax* sporozoites, was excluded from the analysis. We thus focused our
254 analyses on the genes detected in both species in clusters one through three (Fig 5D right and
255 Fig S5B; S9 Table). In total, we identified 155 differentially transcribed genes (adjusted p-value
256 < 0.05), 44 (28%) of which had unknown function (S10 Table). In Fig S6A, we highlight the top
257 differentially transcribed genes within each cluster. At a broad level, genes associated with ion
258 transport (PVP01_0317600 | PF3D7_0721900, PVP01_1014700 | PF3D7_0519200,
259 PVP01_1117400 | PF3D7_1354400, PVP01_1242100 | PF3D7_1464700) displayed greater

260 transcription in ORTHO_C1 *P. vivax* sporozoites (adjusted p-value < 0.05, S10 Table).
261 Alternatively, clusters ORTHO_C2 and ORTHO_C3, various genes associated with locomotion
262 and motility (PVP01_1132600 | PF3D7_0616500, PVP01_1435400 | PF3D7_1216600,
263 PVP01_1218700 | PF3D7_1335900) displayed greater transcription in *P. falciparum* (adjusted
264 p-value < 0.05, S10 Table). Combined with the species-specific genes identified in each cluster,
265 these differences highlight the distinct transcriptomic signatures between *P. vivax* and *P.*
266 *falciparum*.

267 ORTHO_C3 and ORTHO_C4 contained sporozoites with transcriptomic signatures
268 similar to *P. falciparum* activated sporozoites. As ORTHO_C4 was made up of primarily *P. vivax*
269 cells, we sought to assess the extent to which sporozoites in this cluster differed from those in
270 ORTHO_C3 containing both *P. falciparum* and *P. vivax* sporozoites. In total, we identified 98
271 differentially transcribed genes (adjusted p-value < 0.05, S11 Table), several (38/98; 38%) of
272 which have no known function. Interestingly, genes that displayed significantly greater
273 transcription in ORTHO_C4 (Fig 5E) contained Pfam domains associated with translational
274 machinery (PF01200 and PF01253) and RNA-binding proteins (PF00076, PF00806), including
275 mRNA-binding protein PUF2 (PVP01_0526500). PUF2 is an important eukaryotic cell-fate
276 regulator [48], and plays a key-role in translationally repressing transcripts, including *uis3* and
277 *uis4*, required during liver-stage development [49,50]. Interestingly, in the absence of PUF2
278 (Pfam: PF00806::PUF RNA binding repeat), salivary gland sporozoites may initiate
279 exoerythrocytic development independently of the transmission-associated environmental cues
280 [49]. These findings indicate although cellular morphology and invasion strategies are similar in
281 sporozoites from the two species, their respective cellular states, as defined by their
282 transcriptomic signatures, can vary drastically. Whether these differences in transcription play a
283 role in determining the sporozoite's developmental fate upon reaching the liver warrants further
284 investigation.

285 **Comparative analyses of *P. vivax* sporozoite and blood-stage transcriptomes reveals** 286 **conserved and stage-specific signatures**

287 To assess gene usage across different stages of the parasite's life cycle, we compared
288 our sporozoite data with publicly-available scRNA-seq data from *P. vivax* blood stages [26].
289 Before data integration, we realigned the blood-stage sequencing data to account for the UTR
290 additions to the *P. vivax* gene models. As expected, we found a 1.4-fold gain in the number of
291 reads mapping to gene loci when the UTRs were included in the alignment (Fig S7A). Using the
292 cell and gene filtering pipeline established for the sporozoite scRNA-seq data, 12,469 blood-

293 stages parasites were assessed (Fig S7B). We detected a median of 682 genes and 1,442
294 UMIs per cell (Fig S7C). Furthermore, low-dimensional representation of the data confirmed
295 distinct transcriptomic signatures across each sample (Fig S7D).

296 After cell and gene filtering, we integrated the *P. vivax* blood-stage data with our
297 sporozoite data (Fig 6A, Fig S7E) and performed differential transcription analysis. We identified
298 208 differentially transcribed genes, 36 of which remain uncharacterised (minimum expression
299 in 50% of cells, adjusted p-value < 0.1; S13 Table). Among the differentially transcribed genes,
300 59 displayed sporozoite-specific transcription (adjusted p-value < 0.01; S13 Table). As
301 highlighted in Fig 6B, sporozoite-specific markers encoded for transcripts involved in sporozoite
302 development, maturation, and host-cell infection [35–38,51,52]. Furthermore, we identified a
303 small proportion of transcripts (18/208, 8%) present in a similar percentage of sporozoite and
304 erythrocyte forms but with significantly higher transcriptional abundance in sporozoites (Fig 6C;
305 S13 Table). Together, this integrated analysis reveals various stage-specific markers and
306 provides the framework for creating a comprehensive reference map for *P. vivax*.

307 **Discussion**

308 Our scRNA-seq data reveals transcriptional differences among *P. vivax* sporozoites at a
309 resolution previously unattainable with bulk transcriptome-wide approaches. As is expected with
310 droplet-based single-cell capture technologies, a comparison of our scRNA-seq data with that of
311 bulk methods reveals a reduced overall number of genes detected using the single-cell
312 approach [19,20,53]. However, we find that the detection of highly transcribed sporozoite genes
313 is achieved across technologies. Herein we also describe improved approaches for processing
314 and analysing scRNA-seq data useful for the wider community. First, our overall gene detection
315 rate was dramatically improved by including each genes' UTRs in our alignment strategy.
316 Second, clustering and pseudotime analyses were useful for providing new insights into
317 transcription patterns amongst *P. vivax* sporozoites in the salivary glands of mosquitos.

318 Visualising the data in low-dimensional space reveals transcriptional heterogeneity
319 amongst sporozoites. After assigning the sporozoites to clusters and performing differential
320 transcriptional analysis, we identified annotated and unannotated genes underlying this
321 heterogeneity. We found that some sporozoites isolated from the salivary glands show
322 increased transcriptional activity of orthologous genes previously shown to be transcribed in *P.*
323 *berghei* midgut sporozoites [22,25]. We interpret the detection of these markers in *P. vivax* to

324 represent sporozoites that have recently invaded the salivary glands. However, we also found
325 sporozoites that display lower gene usage, which we hypothesize is indicative of maturation.
326 The pseudotime analysis serves to complement the cluster-based assessment of sporozoites.
327 The ordering of sporozoites reveals a gradual decrease in the transcription of most genes.
328 These findings likely recapitulate the transcription changes occurring as the sporozoite
329 transitions from a recently invaded salivary gland sporozoite to a mature one. Translational
330 repression of mRNA is one molecular mechanism sporozoites use to ensure timely production
331 of proteins upon entering its host (reviewed in [54,55]). Our observation of the low number of
332 UMIs and genes detected per cell, which corresponds with other assessments of *Plasmodium*
333 sporozoites at single-cell resolution [22–25], suggests that transcriptional repression may also
334 play a role in the sporozoites' preparation for host invasion.

335 It has been hypothesized that *P. vivax* sporozoites are pre-programmed to become
336 replicating schizonts or hypnozoites [16,17]. However, evidence to support this hypothesis at
337 the molecular level is lacking. We proposed that the transcriptomic analysis of individual
338 sporozoites could test this hypothesis and might support identification of two distinct sporozoite
339 populations, with one destined for normal hepatic development and the other for hypnozoite
340 formation. By comparison, we expected sporozoites from *P. falciparum*, which do not form
341 hypnozoites, would have the first but lack the second population. Our comparative analyses
342 identify a large population of *P. vivax* and *P. falciparum* sporozoites that have conserved
343 patterns in gene usage for various markers implicated in sporozoite biology. These include the
344 genes encoding for sporozoite invasion-associated protein 1, TRAP-like protein, and sporozoite
345 surface protein essential for liver stage development [47,52,56]. Interestingly, distinguishing *P.*
346 *vivax* from *P. falciparum* were a subset (~25%) of *P. vivax* sporozoites transcribing genes (e.g.
347 *puf2*) associated with translational regulation and repression. Noting the role translational
348 repression plays through RNA-binding proteins, including PUF2, in developmental fating in
349 eukaryotes [57], it is intriguing to speculate on possible links between this population and the
350 bradysporozoites [16] proposed to be destined for hypnozoite formation.

351 Future analyses comparing *P. vivax* to the other sporozoites derived from parasites that
352 cause relapsing malaria, such as *P. cynomolgi* and *P. ovale*, may help shed light on the
353 relapsing-specific factors associated with the parasite's developmental fate. However, the
354 differences in methodology used to generate sporozoite scRNA-seq datasets should be
355 considered for these future studies. Of note, scRNA-seq of *P. falciparum* sporozoites was
356 performed after dissecting salivary glands into Schneider's insect medium and then sequencing

357 individual sporozoites following Accudenz purification, immunofluorescent staining and
358 fluorescence-activated cell sorting [23]. In this study we used only a density gradient to purify
359 sporozoites from salivary gland debris before loading them onto a 10x Genomics' controller to
360 generate single-cell RNA libraries. Both collection, purification, and capture workflows involve 1-
361 3 hr of time from dissection to RNA capture, during which time the buffers and temperature used
362 could impact sporozoite activation state [21,58]. Additionally, for both the *P. vivax* and *P.*
363 *falciparum* datasets, pseudotime analysis was found useful for understanding the
364 developmental state of sporozoites, meaning the day, and possibly hour, of dissection post
365 blood-meal could impact comparisons. Despite these differences, we note the substantial
366 overlap in *P. vivax* and *P. falciparum* developmental states in low dimensional space. Still, for
367 future studies these parameters should be standardised as much as possible to remove
368 potential technical artefacts from comparisons.

369 Previous bulk sequencing analyses comparing *P. vivax* sporozoites and blood-stage
370 parasites have revealed distinct transcription patterns between stages [19,59,60]. Here, we
371 corroborate these findings and show that this variation is detectable using scRNA-seq
372 technology. Our comparison of *P. vivax* sporozoites and blood stages highlights differences in
373 transcription that may provide insights into the factors that allow the parasite to persist in
374 different environments. Furthermore, our integrated analysis sets the stage for future additions,
375 with the objective of generating a comprehensive *P. vivax* single-cell atlas. Our data serves as a
376 new resource for the malaria research community, providing a detailed assessment of *P. vivax*
377 gene usage in sporozoites at single-cell resolution. We anticipate that the dataset will serve as a
378 launchpad to address other gaps in knowledge linked to *P. vivax* biology, including the extent to
379 which various strains differ at the transcriptome level and how gene usage in individual
380 sporozoites compares to other stages in the parasite's life cycle.

381 **Materials and methods**

382 **Ethics statement**

383 Research procedures and protocols for obtaining blood from patients were reviewed and
384 approved by the Cambodian National Ethics Committee for Health Research (approval number:
385 #113NECHR). Protocols conformed to the World Medical Association Helsinki Declaration on
386 Ethical Principles for Medical Research Involving Human Subjects (version 2002). Informed
387 written consent was obtained from all volunteers or legal guardians.

388 **Blood samples, mosquitos, and infections**

389 Blood samples from symptomatic patients infected with *P. vivax* were collected at local
390 health facilities in Mondulkiri province (Kaev Seima) in Eastern Cambodia from September to
391 November 2019 (Fig 1A). Following a *P. vivax* gametocyte-containing blood meal, *Anopheles*
392 *dirus* mosquitoes were maintained at 26°C on a 12hr:12hr light:dark cycle and fed with 10%
393 sucrose + 0.05% PABA solution. *An. dirus* found positive for *P. vivax* oocysts at six days post-
394 feeding were transported to the Institut Pasteur of Cambodia Insectary Facility in Phnom Penh,
395 Cambodia, where they were maintained under the same conditions described above.

396 **Sporozoite isolations**

397 *P. vivax* sporozoites were isolated from the salivary glands of female *An. dirus*
398 mosquitoes 16-18 days after an infectious blood-meal. A team of technicians performed
399 dissections for a maximum period of one hour. Generally, ~75 to 100 mosquitoes were
400 dissected in each one-hour sitting. Dissections were performed under a stereomicroscope, and
401 salivary glands were placed in a microcentrifuge tube containing ice-cold Hanks Balanced Salt
402 Solution. Sporozoites were then released from the salivary glands via manual disruption using a
403 microcentrifuge pestle, and immediately purified using a discontinuous density gradient protocol
404 adapted from Kennedy and colleagues [61], and as described previously [25]. After purification,
405 sporozoite mixtures were diluted in HBSS to 1000 sporozoites/mL and were held on ice until
406 further processing.

407 **Hepatocyte infections and liver-stage assessment**

408 *P. vivax* hepatocyte infections were performed as previously described [27]. Briefly,
409 primary human hepatocytes (BioIVT) were seeded 2-3 days prior to infection with 15,000-
410 20,000 sporozoites per well. Media was exchanged with fresh CP media (BioIVT) containing
411 antibiotics the day after infection and every 2-3 days thereafter. At 12 days post-infection,
412 cultures were fixed with 4% paraformaldehyde in 1X PBS. Fixed cultures were stained overnight
413 at 4°C with recombinant mouse anti-*P. vivax* UIS4 antibody diluted 1:25,000 in a stain buffer
414 (0.03% TritonX-100 and 1% (w/v) BSA in 1X PBS) [62]. Cultures were then washed thrice with
415 1X PBS and then stained overnight at 4°C with 1:1000 rabbit anti-mouse AlexaFluor™488-
416 conjugated antibody diluted 1:1,000 in stain buffer. Cultures were then washed thrice with 1X
417 PBS and counterstained with 1 mg/mL Hoechst 33342 to detect parasite and host cell nuclear

418 DNA. Infected hepatocytes were imaged on a Lionheart (Biotek). Quantification of nuclei and
419 liver forms was performed using Gen5 high content analysis software (Biotek).

420 **Single-cell partitioning, library preparation, and sequencing**

421 Approximately 5000-8000 sporozoites were loaded on a version 3- specific Chromium
422 Chip. Chips containing sporozoite suspensions, Gel Beads in Emulsion (GEMs), and reverse
423 transcription reagents were placed in a Chromium controller for single-cell partitioning and
424 cellular barcoding. Barcoded cDNA libraries were generated according to the v3 Chromium
425 Single Cell 3' gene expression protocol. cDNA libraries were loaded on individual flow cell lanes
426 and sequenced using a HiSeq X Ten platform (Illumina) at Macrogen (Seoul, Korea). See Table
427 S1 for sequencing statistics.

428 **Read alignment, cellular barcode assignment, and quantification**

429 The *P. vivax* P01 genome (version 3, October 2020) and its corresponding general
430 feature format (gff) file (which contained UTR coordinates) were downloaded from
431 <ftp://ftp.sanger.ac.uk/pub/genedb/releases/latest/PvivaxP01> and used to create a genome index
432 with STAR (v2.7.3a) [63,64] with options: --runMode genomeGenerate --
433 genomeSAindexNbases 11 --sjdbOverhang 90 (for v3 libraries), or 74 (for libraries derived from
434 [26]). Mapping, demultiplexing and gene quantification was performed with STARsolo and the
435 following options specified: --soloType CB_UMI_Simple --soloCBlen 16 --soloUMIlen 12 (for v3
436 libraries) or 10 (for v2 libraries) --soloCBwhitelist /path/to/10x/version/specific/whitelist --
437 alignIntronMin 1 --alignIntronMax 2756 --soloUMIfiltering MultiGeneUMI --soloFeatures Gene.

438 The *An. dirus* WRAIR2 genome and its corresponding GFF were downloaded from
439 VectorBase (v49). We generated a genome index in STAR (v2.7.3a) with the same parameters
440 as for the *P. vivax* P01 genome.

441 For a schematic of the alignment strategies, refer to Fig S2A and Fig S2C. A summary of
442 read alignment statistics for each sample with- and without- the UTR information are found in S2
443 and S12 Tables for the sporozoite and blood-stage data, respectively.

444 **Filtering and normalisation of scRNA-seq count matrices**

445 The unfiltered (raw) matrix, features, and barcodes files generated from STAR were
446 imported into R (version 4) [65]. We first removed rRNA encoding genes and then used

447 emptyDrops function to distinguish between droplets containing cells and those only with
448 ambient RNA to be discarded [66] with a lower library size limit of 40 to account for the low
449 mRNA amounts in sporozoites (FDR < 0.001). We next removed cells with less than 60 unique
450 genes detected in each cell library. Last, we filtered out lowly detected genes, retaining genes
451 detected in at least two cells with more than two unique molecular identifier (UMI) counts. Post-
452 cell and gene filtering, the data from each replicate were normalised using Seurat's
453 'LogNormalize' function with the default parameters selected [43].

454 **Integration of *P. vivax* sporozoite scRNA-seq data**

455 Filtered, normalised matrices from the three replicates were merged in a manner
456 described in the Seurat (version 4) vignette, *Introduction to scRNA-seq integration*, available on
457 the Satija Lab's website (https://satijalab.org/seurat/articles/integration_introduction.html).
458 Briefly, highly variable features were identified in each replicate using the 'FindVariableFeatures'
459 function with the following parameters selected: selection method = "vst", features = (genes # of
460 detected in dataset) * 0.3. Next, integration anchors were identified using the
461 'FindIntegrationAnchors' function with its default settings. Lastly, using these anchors, the three
462 datasets were integrated using the 'IntegrateData' function with its default settings.

463 **Dimension reduction, clustering, and cluster marker identification**

464 Post integration, data were scaled, and dimension reduction was performed using
465 principal component analysis (PCA) to visualise the data in low-dimensional space. Next, the
466 UMAP dimension reduction was performed using the RunUMAP function with the parameters
467 dims = 1:30 and umap.method = "umap-learn", n.neighbours = 20 and min.dist = 0.5. Next, an
468 unsupervised graph-based clustering approach was used to predict cell communities. First, k-
469 nearest neighbours were identified, and a shared nearest neighbour graph was constructed
470 using the FindNeighbours function under the default settings. Cell communities (clusters) were
471 then identified using the FindClusters function with the Leiden algorithm (algorithm = 4)
472 selected. Clustering was performed at various resolutions (resolution = 0.1:1), and cluster
473 stabilities were assessed using a Clustering tree plot [67].

474 To detect cluster-specific markers (differentially transcribed genes), the Seurat function
475 FinalAllMarkers was used with the following parameters: test.use = "wilcox", min.pct = 0.3,
476 min.diff.pct = 0.1, only.pos = TRUE, assay = "originalexp". Differentially transcribed genes were
477 considered significant if the adjusted p value was below 0.05.

478 **Trajectory analysis**

479 To infer the developmental trajectory of sporozoites, we used the Slingshot package [44]
480 to uncover the global structure of clusters of cells and convert this structure into a smoothed
481 lineage representing "pseudotime". Lineages were first generated using the getLineages function
482 on the UMAP embeddings generated previously (described in *Dimension reduction, clustering*
483 *and cluster marker identification*). Cluster C1 was selected as the starting cluster because it
484 contained putative immature salivary gland sporozoite markers. Next, smoothed lineage curves
485 were constructed using the getCurves function with the default parameters. We then used the
486 tradeSeq package [45] to analyse transcription along the trajectory. To this end, we ran the fitGAM
487 function on the SlingshotDataset to fit a negative binomial general additive model on the data.
488 Based on the fitted models, the AssociationTest with default settings selected was used to test
489 transcription changes across pseudotime. Genes were considered significantly associated with a
490 change over pseudotime at a false discovery rate below 0.01.

491 **Inter-species comparison of *Plasmodium* spp. sporozoites**

492 We grouped orthologous genes of *P. vivax* P01, *P. cynomolgi* M, *P. cynomolgi* B, *P.*
493 *berghei* ANKA, *P. falciparum* 3D7, *P. yoelli yoelli* 17X, *P. chabaudi chabaudi*, *P. knowlesi* H, *P.*
494 *malariae* UG01, *P. ovale curtisi* GH01 and *Toxoplasma gondii* ME49 using OrthoFinder [46].
495 Parameters were kept at default and gene fasta files for input were obtained from either
496 *PlasmoDB* or *ToxoDB*, release version 51. From the 'Orthogroups' analysis, the tab-delimited
497 output file was used to extract the species-specific gene IDs for *P. vivax* and *P. falciparum* and
498 match these with a universal orthogroup ID (S7 Table). We used this orthogroup ID to replace
499 rownames corresponding to *P. vivax* or *P. falciparum* gene IDs in the count matrices of *P. vivax*
500 sporozoites (this study) and *P. falciparum* sporozoites [23]. Orthogroup IDs for merge were only
501 retained if they had only one entry per species. In a *P. vivax*-centric approach, we retained
502 orthogroup IDs if either *P. falciparum*, *P. berghei* ANKA, *P. cynomolgi* M or *P. cynomolgi* B had
503 at least one corresponding gene orthologue. *P. vivax* data were processed as described earlier
504 (section *Filtering and normalization of scRNA-seq count matrices*) and *P. falciparum* data was
505 obtained from
506 https://github.com/vhowick/pf_moz_stage_atlas/tree/master/counts_and_metadata. Following
507 the replacement of gene IDs with new orthogroup IDs, we additionally performed another round
508 of cell filtering to account for changes in gene count per cell information with the removal of
509 some genes without equivalent orthogroup IDs. Data integration were also performed as

510 described earlier (section *Integration of P. vivax sporozoite scRNA-seq datasets*). The *P. vivax*
511 data were randomly subset (500 sporozoites per replicate) for subsequent analyses to match
512 the proportion of cells in the *P. falciparum* dataset prior to integration and account for the
513 disproportionate number of sporozoites between the two species. Clusters of sporozoites were
514 identified using 'FindNeighbours' function using the 'pca' reduction, dims = 1:15, k.param = 20,
515 and 'FindClusters' function with the Leiden clustering algorithm (algorithm = 4) at a resolution of
516 0.2. Marker genes for the defined clusters were identified with either the
517 'FinderConservedMarkers' or 'FindMarkers' functions (Seurat) using a Wilcoxon Rank Sum test.
518 The number of cells, percent difference, and fold-change parameters for each of the analyses
519 are indicated in the R markdown document provided.

520 **Integration of *P. vivax* sporozoite and blood stage scRNA-seq data**

521 Filtering and normalisation for the *P. vivax* blood-stage scRNA-seq data was performed
522 in the same manner used for the sporozoite scRNA-seq data described in *Filtering and*
523 *normalization of scRNA-seq count matrices*. Of the 10 *P. vivax* blood-stage replicates, we used
524 the 7 generated from samples without chloroquine treatment. Before integration, variable
525 features for the combined sporozoite (3) and combined blood-stage (7) datasets were identified
526 using the FindVariableFeatures function with the following parameters: selection method = "vst",
527 features = (genes # of detected in dataset) * 0.3. Next, we used the FindIntegrationAnchors
528 function to identify anchors between the sporozoite and blood-stage datasets. Guided by the
529 recommendations provided by the Satija lab's vignette *Fast integration using reciprocal PCA*
530 *(RPCA)* (https://satijalab.org/seurat/articles/integration_rpca.html), namely when cells in one
531 dataset have no matching type in the other, we selected the RPCA parameter in
532 FindIntegrationAnchors (reduction = "rpca") to identify anchors between the sporozoite and
533 blood-stage data. Last, using these anchors, the datasets were integrated using the
534 IntegrateData function with its default settings. Assessment of differentially transcribed genes in
535 sporozoite and blood-stage parasites were performed in the same manner described in
536 *Differential genes transcription analysis* with additional parameters indicated in the provided R
537 markdown files.

538 **Contact for reagent and resource sharing**

539 Further information and requests for resources and reagents should be directed to the Lead
540 Contact, Ivo Mueller (e-mail: mueller@wehi.edu.au).

541 **Data Availability:**

542 All raw sequencing data generated from *P. vivax* sporozoites in this study will be deposited and
543 accessible in the European Nucleotide Archive (www.ebi.ac.uk/ena/) upon acceptance of the
544 manuscript.

545 *P. vivax* blood-stage scRNA-seq data were downloaded from NCBI's Short Read Archive
546 (Bioproject ID: PRJNA603327).

547 *P. falciparum* sporozoite scRNA-seq data were obtained from:
548 https://github.com/vhowick/pf_moz_stage_atlas

549 Scripts and supporting files will be available on GitHub upon acceptance of the manuscript.

550 Archived scripts and output files as at time of publication will be available on Zenodo.com upon
551 acceptance of the manuscript.

552 **Acknowledgments**

553 We thank the *P. vivax* patients of Mondulkiri Province, Cambodia, for participating in this study.
554 We thank the Institut Pasteur insectary staff (Makara Pring, Koeun Kaing, Nora Sambath) for
555 *An. dirus* mosquito colony maintenance, the laboratory staff (Eakpor Piv, Chansophea Chhin,
556 Sreyvouch Phen, Chansovandan Chhun, Sivcheng Phal, Baura Tat) for assistance with the
557 mosquito dissections and the *in vitro* assays, and the field site manager (Saorin Kim) for
558 logistical assistance.

559 **References**

- 560 1. World Health Organization. World malaria report 2020. WHO. 2020. Available:
561 <https://www.who.int/publications/i/item/9789240015791>
- 562 2. Battle KE, Baird KJ. The global burden of Plasmodium vivax malaria is obscure and
563 insidious. PLOS Medicine. 2021;18: e1003799. doi:10.1371/JOURNAL.PMED.1003799
- 564 3. Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, et al. Mapping the
565 global endemicity and clinical burden of Plasmodium vivax, 2000–17: a spatial and
566 temporal modelling study. The Lancet. 2019;394: 332–343. doi:10.1016/S0140-
567 6736(19)31096-7
- 568 4. Weiss DJ, Lucas TCD, Nguyen M, Nandi AK, Bisanzio D, Battle KE, et al. Mapping the
569 global prevalence, incidence, and mortality of Plasmodium falciparum, 2000–17: a spatial
570 and temporal modelling study. The Lancet. 2019;394: 322–331. doi:10.1016/S0140-

- 571 6736(19)31097-9/ATTACHMENT/33EB90A6-D959-4261-8281-
572 5E12C6273433/MMC1.PDF
- 573 5. Amino R, Thiberge S, Martin B, Celli S, Shorte S, Frischknecht F, et al. Quantitative
574 imaging of Plasmodium transmission from mosquito to mammal. *Nature Medicine*.
575 2006;12: 220–224. doi:10.1038/nm1350
- 576 6. Krotoski WA. Discovery of the hypnozoite and a new theory of malarial relapse.
577 *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1985;79: 1.
578 doi:10.1016/0035-9203(85)90221-4/2/79-1-1.PDF.GIF
- 579 7. Krotoski WA, Collins WE, Bray RS, Garnham PC, Cogswell FB, Gwadz RW, et al.
580 Demonstration of hypnozoites in sporozoite-transmitted *Plasmodium vivax* infection. *The*
581 *American journal of tropical medicine and hygiene*. 1982;31: 1291–1293.
582 doi:10.4269/AJTMH.1982.31.1291
- 583 8. Robinson LJ, Wampfler R, Betuela I, Karl S, White MT, Li Wai Suen CSN, et al.
584 Strategies for Understanding and Reducing the *Plasmodium vivax* and *Plasmodium ovale*
585 Hypnozoite Reservoir in Papua New Guinean Children: A Randomised Placebo-
586 Controlled Trial and Mathematical Model. *PLOS Medicine*. 2015;12: e1001891.
587 doi:10.1371/journal.pmed.1001891
- 588 9. Adekunle AI, Pinkevych M, McGready R, Luxemburger C, White LJ, Nosten F, et al.
589 Modeling the Dynamics of *Plasmodium vivax* Infection and Hypnozoite Reactivation In
590 Vivo. *PLOS Neglected Tropical Diseases*. 2015;9: e0003595.
591 doi:10.1371/journal.pntd.0003595
- 592 10. Commons RJ, Simpson JA, Watson J, White NJ, Price RN. Estimating the Proportion of
593 *Plasmodium vivax* Recurrences Caused by Relapse: A Systematic Review and Meta-
594 Analysis. *American Journal of Tropical Medicine and Hygiene*. 2020;103: 1094–1099.
595 doi:10.4269/ajtmh.20-0186
- 596 11. Sattabongkot J, Suansomjit C, Nguitragool W, Sirichaisinthop J, Warit S, Tiensuwan M, et
597 al. Prevalence of asymptomatic *Plasmodium* infections with sub-microscopic parasite
598 densities in the northwestern border of Thailand: A potential threat to malaria elimination.
599 *Malaria Journal*. 2018;17. doi:10.1186/s12936-018-2476-1
- 600 12. White MT, Walker P, Karl S, Hetzel MW, Freeman T, Waltmann A, et al. Mathematical
601 modelling of the impact of expanding levels of malaria control interventions on
602 *Plasmodium vivax*. *Nature Communications* 2018 9:1. 2018;9: 1–10. doi:10.1038/s41467-
603 018-05860-8
- 604 13. Huldén L, Huldén L, Heliövaara K. Natural relapses in vivax malaria induced by
605 *Anopheles* mosquitoes. *Malaria journal*. 2008;7. doi:10.1186/1475-2875-7-64
- 606 14. Battle KE, Karhunen MS, Bhatt S, Gething PW, Howes RE, Golding N, et al.
607 Geographical variation in *Plasmodium vivax* relapse. *Malaria Journal*. 2014;13.
608 doi:10.1186/1475-2875-13-144
- 609 15. White NJ. Determinants of relapse periodicity in *Plasmodium vivax* malaria. *Malaria*
610 *Journal*. 2011. doi:10.1186/1475-2875-10-297

- 611 16. Lysenko AJ, Beljaev AE, Rybalka VM. Population studies of *Plasmodium vivax*. 1. The
612 theory of polymorphism of sporozoites and epidemiological phenomena of tertian malaria.
613 Bulletin of the World Health Organization. 1977.
- 614 17. Ungureanu E, Killick-Kendrick R, Garnham PCC, Branzei P, Romanescu C, Shute PG.
615 Prepatent periods of a tropical strain of *Plasmodium vivax* after inoculations of tenfold
616 dilutions of sporozoites. Transactions of the Royal Society of Tropical Medicine and
617 Hygiene. 1976;70: 482–483. doi:10.1016/0035-9203(76)90133-4
- 618 18. Mikolajczak SA, Vaughan AM, Kangwanransan N, Roobsoong W, Fishbaugher M,
619 Yimamnuaychok N, et al. *Plasmodium vivax* liver stage development and hypnozoite
620 persistence in human liver-chimeric mice. Cell Host and Microbe. 2015;17: 526–535.
621 doi:10.1016/j.chom.2015.02.011
- 622 19. Muller I, Jex AR, Kappe SHI, Mikolajczak SA, Sattabongkot J, Patrapuvich R, et al.
623 Transcriptome and histone epigenome of *Plasmodium vivax* salivary-gland sporozoites
624 point to tight regulatory control and mechanisms for liver-stage differentiation in relapsing
625 malaria. International Journal for Parasitology. 2019;49: 501–513.
626 doi:10.1016/J.IJPARA.2019.02.007
- 627 20. Westenberger SJ, McClean CM, Chattopadhyay R, Dharia N v., Carlton JM, Barnwell
628 JW, et al. A Systems-Based Analysis of *Plasmodium vivax* Lifecycle Transcription from
629 Human to Mosquito. PLoS Neglected Tropical Diseases. 2010;4: e653.
630 doi:10.1371/journal.pntd.0000653
- 631 21. Roth A, Adapa SR, Zhang M, Liao X, Saxena V, Goffe R, et al. Unraveling the
632 *Plasmodium vivax* sporozoite transcriptional journey from mosquito vector to human host.
633 Scientific Reports. 2018;8: 12183. doi:10.1038/s41598-018-30713-1
- 634 22. Bogale HN, Pascini T v., Kanatani S, Sá JM, Wellems TE, Sinnis P, et al. Transcriptional
635 heterogeneity and tightly regulated changes in gene expression during *Plasmodium*
636 *berghei* sporozoite development. Proceedings of the National Academy of Sciences of
637 the United States of America. 2021;118. doi:10.1073/pnas.2023438118
- 638 23. Real E, Howick VM, Dahalan FA, Witmer K, Cudini J, Andradi-Brown C, et al. A single-
639 cell atlas of *Plasmodium falciparum* transmission through the mosquito. Nature
640 Communications. 2021;12: 3196. doi:10.1038/s41467-021-23434-z
- 641 24. Howick VM, Russell AJC, Andrews T, Heaton H, Reid AJ, Natarajan K, et al. The Malaria
642 Cell Atlas: Single parasite transcriptomes across the complete *Plasmodium* life cycle.
643 Science. 2019;365: eaaw2619. doi:10.1126/SCIENCE.AAW2619
- 644 25. Ruberto AA, Bourke C, Merienne N, Obadia T, Amino R, Mueller I. Single-cell RNA
645 sequencing reveals developmental heterogeneity among *Plasmodium berghei*
646 sporozoites. Scientific Reports. 2021;11: 4127. doi:10.1038/s41598-021-82914-w
- 647 26. Sà JM, Cannon M v., Caleon RL, Wellems TE, Serre D. Single-cell transcription analysis
648 of *Plasmodium vivax* blood-stage parasites identifies stage- And species-specific profiles
649 of expression. PLoS Biology. 2020;18: e3000711. doi:10.1371/journal.pbio.3000711
- 650 27. Roth A, Maher SP, Conway AJ, Ubalee R, Chaumeau V, Andolina C, et al. A
651 comprehensive model for assessment of liver stage therapies targeting *Plasmodium*

- 652 vivax and *Plasmodium falciparum*. *Nature Communications*. 2018;9: 1837.
653 doi:10.1038/s41467-018-04221-9
- 654 28. Klein AM, Mazutis L, Akartuna I, Tallapragada N, Veres A, Li V, et al. Droplet barcoding
655 for single-cell transcriptomics applied to embryonic stem cells. *Cell*. 2015;161: 1187–
656 1201. doi:10.1016/j.cell.2015.04.044
- 657 29. Macosko EZ, Basu A, Satija R, Nemesh J, Shekhar K, Goldman M, et al. Highly parallel
658 genome-wide expression profiling of individual cells using nanoliter droplets. *Cell*.
659 2015;161: 1202–1214. doi:10.1016/j.cell.2015.05.002
- 660 30. Zheng GXY, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, et al. Massively
661 parallel digital transcriptional profiling of single cells. *Nature Communications*. 2017;8.
662 doi:10.1038/ncomms14049
- 663 31. Shields EJ, Sorida M, Sheng L, Sieriebriennikov B, Ding L, Bonasio R. Genome
664 annotation with long RNA reads reveals new patterns of gene expression in an ant brain.
665 *bioRxiv*. 2021; 2021.04.20.440671. doi:10.1101/2021.04.20.440671
- 666 32. Packer JS, Zhu Q, Huynh C, Sivaramakrishnan P, Preston E, Dueck H, et al. A lineage-
667 resolved molecular atlas of *C. Elegans* embryogenesis at single-cell resolution. *Science*.
668 2019;365. doi:10.1126/science.aax1971
- 669 33. Siegel S v., Chappell L, Hostetler JB, Amaratunga C, Suon S, Böhme U, et al. Analysis of
670 *Plasmodium vivax* schizont transcriptomes from field isolates reveals heterogeneity of
671 expression of genes involved in host-parasite interactions. *Scientific Reports*. 2020;10:
672 16667. doi:10.1038/s41598-020-73562-7
- 673 34. Kivioja T, Vähärautio A, Karlsson K, Bonke M, Enge M, Linnarsson S, et al. Counting
674 absolute numbers of molecules using unique molecular identifiers. *Nature methods*.
675 2011;9: 72–74. doi:10.1038/NMETH.1778
- 676 35. Sinnis P, Clavijo P, Fenyö D, Chait BT, Cerami C, Nussenzweig V. Structural and
677 functional properties of region II-plus of the malaria circumsporozoite protein. *Journal of*
678 *Experimental Medicine*. 1994;180. doi:10.1084/jem.180.1.297
- 679 36. Coppi A, Natarajan R, Pradel G, Bennett BL, James ER, Roggero MA, et al. The malaria
680 circumsporozoite protein has two functional domains, each with distinct roles as
681 sporozoites journey from mosquito to mammalian host. *Journal of Experimental Medicine*.
682 2011;208. doi:10.1084/jem.20101488
- 683 37. Ishino T, Yano K, Chinzei Y, Yuda M. Cell-passage activity is required for the malarial
684 parasite to cross the liver sinusoidal cell layer. *PLoS Biology*. 2004;2.
685 doi:10.1371/journal.pbio.0020004
- 686 38. Talman AM, Lacroix C, Marques SR, Blagborough AM, Carzaniga R, Ménard R, et al.
687 PbGEST mediates malaria transmission to both mosquito and vertebrate host. *Molecular*
688 *Microbiology*. 2011;82. doi:10.1111/j.1365-2958.2011.07823.x
- 689 39. Mueller AK, Camargo N, Kaiser K, Andorfer C, Frevert U, Matuschewski K, et al.
690 *Plasmodium* liver stage developmental arrest by depletion of a protein at the parasite–

- 691 host interface. *Proceedings of the National Academy of Sciences*. 2005;102: 3022–3027.
692 doi:10.1073/PNAS.0408442102
- 693 40. Matuschewski K, Ross J, Brown SM, Kaiser K, Nussenzweig V, Kappe SHI. Infectivity-
694 associated Changes in the Transcriptional Repertoire of the Malaria Parasite Sporozoite
695 Stage *. *Journal of Biological Chemistry*. 2002;277: 41948–41953.
696 doi:10.1074/JBC.M207315200
- 697 41. Real E, Rodrigues L, Cabal GG, Enguita FJ, Mancio-Silva L, Mello-Vieira J, et al.
698 *Plasmodium* UIS3 sequesters host LC3 to avoid elimination by autophagy in hepatocytes.
699 *Nature Microbiology* 2017 3:1. 2017;3: 17–25. doi:10.1038/s41564-017-0054-x
- 700 42. Traag VA, Waltman L, van Eck NJ. From Louvain to Leiden: guaranteeing well-connected
701 communities. *Scientific Reports*. 2019;9: 1–12. doi:10.1038/s41598-019-41695-z
- 702 43. Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, et al.
703 *Comprehensive Integration of Single-Cell Data*. *Cell*. 2019;177: 1888-1902.e21.
704 doi:10.1016/j.cell.2019.05.031
- 705 44. Street K, Risso D, Fletcher RB, Das D, Ngai J, Yosef N, et al. Slingshot: Cell lineage and
706 pseudotime inference for single-cell transcriptomics. *BMC Genomics*. 2018;19.
707 doi:10.1186/s12864-018-4772-0
- 708 45. van den Berge K, Roux de Bézieux H, Street K, Saelens W, Cannoodt R, Saeys Y, et al.
709 *Trajectory-based differential expression analysis for single-cell sequencing data*. *Nature*
710 *Communications*. 2020;11. doi:10.1038/s41467-020-14766-3
- 711 46. Emms DM, Kelly S. OrthoFinder: Phylogenetic orthology inference for comparative
712 genomics. *Genome Biology*. 2019;20: 238. doi:10.1186/s13059-019-1832-y
- 713 47. Engelmann S, Silvie O, Matuschewski K. Disruption of *Plasmodium* sporozoite
714 transmission by depletion of sporozoite invasion-associated protein 1. *Eukaryotic Cell*.
715 2009;8. doi:10.1128/EC.00347-08
- 716 48. Zhang B, Gallegos M, Puoti A, Durkin E, Fields S, Kimble J, et al. A conserved RNA-
717 binding protein that regulates sexual fates in the *C. elegans* hermaphrodite germ line.
718 *Nature* 1997 390:6659. 1997;390: 477–484. doi:10.1038/37297
- 719 49. Gomes-Santos CSS, Braks J, Prudêncio M, Carret C, Gomes AR, Pain A, et al.
720 *Transition of Plasmodium sporozoites into liver stage-like forms is regulated by the RNA*
721 *binding protein Pumilio*. *PLoS Pathogens*. 2011;7. doi:10.1371/journal.ppat.1002046
- 722 50. Lindner SE, Mikolajczak SA, Vaughan AM, Moon W, Joyce BR, Sullivan WJ, et al.
723 *Perturbations of Plasmodium Puf2 expression and RNA-seq of Puf2-deficient sporozoites*
724 *reveal a critical role in maintaining RNA homeostasis and parasite transmissibility*.
725 *Cellular Microbiology*. 2013;15: 1266–1283. doi:10.1111/cmi.12116
- 726 51. Cerami C, Frevert U, Sinnis P, Takacs B, Clavijo P, Santos MJ, et al. The basolateral
727 domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite
728 protein of *plasmodium falciparum* sporozoites. *Cell*. 1992;70. doi:10.1016/0092-
729 8674(92)90251-7

- 730 52. Al-Nihmi FMA, Kolli SK, Reddy SR, Mastan BS, Togiri J, Maruthi M, et al. A Novel and
731 Conserved Plasmodium Sporozoite Membrane Protein SPELD is Required for Maturation
732 of Exo-erythrocytic Forms. *Scientific Reports*. 2017;7. doi:10.1038/srep40407
- 733 53. Haque A, Engel J, Teichmann SA, Lönnberg T. A practical guide to single-cell RNA-
734 sequencing for biomedical research and clinical applications. *Genome Medicine*. BioMed
735 Central Ltd.; 2017. pp. 1–12. doi:10.1186/s13073-017-0467-4
- 736 54. Schäfer C, Zanghi G, Vaughan AM, Kappe SHI. Plasmodium vivax Latent Liver Stage
737 Infection and Relapse: Biological Insights and New Experimental Tools . *Annual Review*
738 *of Microbiology*. 2021;75. doi:10.1146/annurev-micro-032421-061155
- 739 55. Briquet S, Marinach C, Silvie O, Vaquero C. Preparing for Transmission: Gene
740 Regulation in Plasmodium Sporozoites. *Frontiers in Cellular and Infection Microbiology*.
741 *Frontiers Media S.A.*; 2021. p. 907. doi:10.3389/fcimb.2020.618430
- 742 56. Heiss K, Nie H, Kumar S, Daly TM, Bergman LW, Matuschewski K, et al. Functional
743 Characterization of a Redundant Plasmodium TRAP Family Invasin, TRAP-Like Protein,
744 by Aldolase Binding and a Genetic Complementation Test Mailing address for.
745 EUKARYOTIC CELL. 2008;7: 1062–1070. doi:10.1128/EC.00089-08
- 746 57. Kong J, Lasko P. Translational control in cellular and developmental processes. *Nature*
747 *Reviews Genetics* 2012 13:6. 2012;13: 383–394. doi:10.1038/nrg3184
- 748 58. Hegge S, Kudryashev M, Barniol L, Frischknecht F. Key factors regulating Plasmodium
749 berghei sporozoite survival and transformation revealed by an automated visual assay.
750 *FASEB journal : official publication of the Federation of American Societies for*
751 *Experimental Biology*. 2010;24: 5003–5012. doi:10.1096/FJ.10-164814
- 752 59. Bozdech Z, Mok S, Hu G, Imwong M, Jaidee A, Russell B, et al. The transcriptome of
753 Plasmodium vivax reveals divergence and diversity of transcriptional regulation in malaria
754 parasites. *Proceedings of the National Academy of Sciences of the United States of*
755 *America*. 2008;105: 16290–16295. doi:10.1073/pnas.0807404105
- 756 60. Zhu L, Mok S, Imwong M, Jaidee A, Russell B, Nosten F, et al. New insights into the
757 Plasmodium vivax transcriptome using RNA-Seq. *Scientific Reports*. 2016;6.
758 doi:10.1038/srep20498
- 759 61. Kennedy M, Fishbaugher ME, Vaughan AM, Patrapuvich R, Boonhok R, Yimamnuaychok
760 N, et al. A rapid and scalable density gradient purification method for Plasmodium
761 sporozoites. *Malaria Journal*. 2012;11: 421. doi:10.1186/1475-2875-11-421
- 762 62. Schafer C, Dambrauskas N, Steel RW, Carbonetti S, Chuenchob V, Flannery EL, et al. A
763 recombinant antibody against Plasmodium vivax UIS4 for distinguishing replicating from
764 dormant liver stages. *Malaria Journal*. 2018;17: 370. doi:10.1186/s12936-018-2519-7
- 765 63. Kaminow B, Yunusov D, Dobin A. STARsolo: accurate, fast and versatile
766 mapping/quantification of single-cell and single-nucleus RNA-seq data. *bioRxiv*. 2021;
767 2021.05.05.442755. doi:10.1101/2021.05.05.442755

- 768 64. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: Ultrafast
769 universal RNA-seq aligner. *Bioinformatics*. 2013;29: 15–21.
770 doi:10.1093/bioinformatics/bts635
- 771 65. R Core Team. R: A Language and Environment for Statistical Computing. Vienna,
772 Austria: R Foundation for Statistical Computing; 2013. Available: www.R-project.org
- 773 66. Lun ATL, Riesenfeld S, Andrews T, Dao TP, Gomes T, Marioni JC. EmptyDrops:
774 Distinguishing cells from empty droplets in droplet-based single-cell RNA sequencing
775 data. *Genome Biology*. 2019;20: 63. doi:10.1186/s13059-019-1662-y
- 776 67. Zappia L, Oshlack A. Clustering trees: a visualization for evaluating clusterings at multiple
777 resolutions. *GigaScience*. 2018;7. doi:10.1093/gigascience/giy083

778

779 **Supporting information Captions**

780

781 S1 Table. Illumina sequencing metrics.

782 S2 Table. Alignment statistics for *P. vivax* sporozoite scRNA-seq data.

783 S3 Table. Comparison of *P. vivax* sporozoite gene metrics with- and without-UTR information
784 across each replicate

785 S4 Table. Overlap across datasets of additional genes detected in *P. vivax* sporozoites with
786 UTR information and total counts in each replicate

787 S5 Table. Marker genes in *P. vivax* sporozoites across clusters

788 S6 Table. Genes identified as differentially expressed across pseudotime with corresponding
789 summary statistics.

790 S7 Table. Summary of orthologous genes used in cross-species integrated analysis.

791 S8 Table. Conserved markers across *P. vivax* and *P. falciparum*.

792 S9 Table. Overlapping and species-specific genes detected in ORTHO clusters.

793 S10 Table. Genes differentially expressed between *P. vivax* and *P. falciparum* in each cluster.

794 S11 Table. Genes differentially expressed between sporozoites in clusters ORTHO_C3 and
795 ORTHO_C4. Positive avg_log2FC: greater expression in ORTHO_C3.

796 S12 Table. Alignment statistics for *P. vivax* blood-stage scRNA-seq data downloaded from SRA
797 (PRJNA603327) and remapped using STARsolo.

798 S13 Table. Differential gene expression between *P. vivax* sporozoites and erythrocytic-stage
799 parasites.

800 Supplementary Figure 1. Related to Figure 1. Strategy used to assess *P. vivax* sporozoite
801 transcriptomes at single-cell resolution.

802 Supplementary Figure 2. Related to Figure 1. Strategy used to assess *P. vivax* sporozoite
803 transcriptomes at single-cell resolution.

804 Supplementary Figure 3. Related to Figure 2. Analysis of *P. vivax* sporozoite gene expression at
805 single-cell resolution

806 Supplementary Figure 4. Related to Figure 3. Clustering and differential expression analysis of
807 *P. vivax* sporozoites.

808 Supplementary Figure 5. Related to Figure 5. Integration of *P. vivax* and *P. falciparum*
809 sporozoite datasets.

810 Supplementary Figure 6. Related to Figure 5. Integration of *P. vivax* and *P. falciparum*
811 sporozoite datasets.

812 Supplementary Figure 7. Related to Figure 6. Integration and comparative analyses of *P. vivax*
813 sporozoite and blood-stage parasite transcriptomes.




Figure 1. Strategy used to assess *P. vivax* sporozoite transcriptomes at single-cell resolution.

(A) Schematic illustrating the geographical region, sample preparation and sequencing pipeline used to capture single-cell transcriptomes of *P. vivax* sporozoites. (B) Percentage of reads aligning to the *P. vivax* P01 genome and transcriptome (with- or without- UTR information) across the three replicates. (C) 'Pseudobulk' visualisation of UMI counts aligned to *P. vivax* P01 transcriptome without (-) or with (+) UTR information. (D) Number of sporozoite transcriptomes retained post cell- and gene-filtering. (E) Number of unique and overlapping genes detected across scRNA-seq datasets. (F) Comparison of orthologous up-regulated in infective sporozoites (UIS) genes (obtained from *P. berghei*) across three high-throughput sequencing technologies (microarray: Westenberger *et al.* 2009, bulk-RNA seq: Muller *et al.* 2019 and single-cell RNA seq; current study). To account for the differences in the total number of genes detected across technologies, gene expression values were compared using percentile ranks. *GEST*: gamete egress and sporozoite traversal; *CNA*: serine/threonin protein phosphatase 2B catalytic subunit A; *HoMu*: RNA-binding protein Musashi; UTR: untranslated region.






Figure 2. Analysis of *P. vivax* sporozoite gene expression at single-cell resolution.

(A) Violin plots (with boxplot overlaid) showing the distribution of unique molecular identifiers (UMIs) per cell (left), and genes detected per cell (right). (B) UMAPs of *P. vivax* sporozoite transcriptomes, visualized per replicate (upper) and combined (lower). Red-lines represent the density of cells represented in low dimensional space. (C) UMAPs of *P. vivax* transcriptomes colored by total number of UMIs (left) and total number of genes detected (right) per cell. (D) UMAPs of *P. vivax* sporozoite transcriptomes. Cells colored by expression of various genes implicated in sporozoite biology. Scale bar: normalised expression. *csp*: circumsporozoite protein; *uis3*: upregulated-in-infective sporozoites 3; *uis4*: upregulated-in-infective sporozoites 4; *celtos*: cell-traversal protein for ookinetes and sporozoites; *gest*: gamete egress and sporozoite traversal; *spect1*: sporozoite microneme protein essential for cell traversal 1; *puf2*: mRNA-binding protein PUF2; *alba1*: DNA/RNA binding protein Alba1; *alba4*: DNA/RNA binding protein alba4.

A



B



C




Figure 3. Clustering and differential gene expression analysis of *P. vivax* sporozoites.

(A) UMAP of integrated *P. vivax* sporozoite transcriptomes coloured by cluster (Leiden algorithm; resolution parameter = 0.1). (B) UMAP of integrated *P. vivax* sporozoite transcriptomes split by replicate (upper) and the percentage of sporozoites in each cluster from the replicate (lower). (C) Dot plot showing topmarkers that distinguish each of the three clusters. The size of the dot corresponds to the percentage of sporozoites expressing the gene. Scale bar: normalised expression, scaled.




Figure 4. Pseudotime analysis of *P. vivax* sporozoites.

(A) UMAP *P. vivax* sporozoite transcriptomes coloured by progression along pseudotime. Colour scale matches pseudotime in panel B; where darker cells are representative of cells placed earlier in pseudotime and lighter cells are projected later along the pseudotime trajectory. (B) Distribution of cells along pseudotime faceted by replicate. (C) Heatmap showing genes differentially express across pseudotime (Data shown: mean pseudobulk >2000, waldStat >200 and FDR < 0.01). Genes are hierarchically clustered based on their pseudotime expression profile. Scale bar: normalized expression.





Figure 5. Integration of *P. vivax* and *P. falciparum* sporozoite datasets.

(A) UMAPs of integrated *P. vivax* and *P. falciparum* data. Top: split and coloured by species. Bottom: split by replicate (*P. vivax*) or sporozoite status (*P. falciparum*). (B) UMAP of integrated *P. vivax* and *P. falciparum* data coloured by cluster. (C) Number of cells contributing to each cluster from *P. vivax* and *P. falciparum* samples. (D) Number of species-specific genes (left) and conserved one-to-one orthologs (right) detected in each cluster. (E) Differentially expressed genes between clusters ORTHO_C3 and ORTHO_C4 with known Pfam domains. . Scale bar: normalized expression.

A



B



C





Figure 6. Integration and comparative analyses of *P. vivax* sporozoite and blood-stage parasite transcriptomes.


(A) UMAP of integrated *P. vivax* sporozoite and blood-stage parasite transcriptomic data. (B) Dot plot highlighting the top differentially expressed genes with stage-specific expression patterns (absolute difference in gene detection > 65% between sporozoites and blood stages). (C) Dot plot highlighting the top differentially expressed genes with detection in similar percentages of cells between sporozoites and blood-stage parasites. Scale bar: normalized expression.




[Click here to access/download](#)

Supporting Information

[PvSpz_SupplementaryFigures_20211217.pdf](#)





[Click here to access/download](#)

Supporting Information

PvSpz_SupplementaryTables_20211217.xlsx

